The portfolio maintains a sizable cost advantage over competitors, priced within the second-cheapest fee quintile among peers.
Janus Henderson Global Life Sciences I JFNIX
- NAV / 1-Day Return 71.32 / −0.39 %
- Total Assets 5.4 Bil
-
Adj. Expense Ratio
- Expense Ratio 0.770%
- Distribution Fee Level Below Average
- Share Class Type Institutional
- Category Health
- Investment Style Large Growth
- Min. Initial Investment 1.0 Mil
- Status Open
- TTM Yield 0.15%
- Turnover 34%
USD | NAV as of Apr 24, 2024 | 1-Day Return as of Apr 24, 2024, 10:23 PM GMT+0
Morningstar’s Analysis JFNIX
Will JFNIX outperform in future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 37.3
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
---|---|---|---|
Eli Lilly and Co | 6.63 | 346.8 Mil | Healthcare |
UnitedHealth Group Inc | 5.96 | 311.6 Mil | Healthcare |
Novo Nordisk A/S Class B | 4.81 | 251.3 Mil | Healthcare |
Merck & Co Inc | 3.56 | 186.1 Mil | Healthcare |
AstraZeneca PLC | 3.56 | 186.0 Mil | Healthcare |
AbbVie Inc | 3.21 | 168.0 Mil | Healthcare |
Abbott Laboratories | 2.49 | 129.9 Mil | Healthcare |
Sanofi SA | 2.46 | 128.7 Mil | Healthcare |
Vertex Pharmaceuticals Inc | 2.37 | 124.1 Mil | Healthcare |
Boston Scientific Corp | 2.29 | 119.5 Mil | Healthcare |